Author: Timothy Donahue

  • Ispire Technology Reports 2023 Annual Earnings

    Ispire Technology Reports 2023 Annual Earnings

    Ispire Technology Inc, a vapor technology, has announced its financial results for the fiscal year 2023, which ended on June 30, 2023.

    Fiscal year 2023 marked a significant milestone for Ispire, with a 100.4% and 10.9% surge in cannabis and tobacco vaping products revenues, respectively from Fiscal year 2022, according to a press note.

    Overall revenue Increased 31.2%. The growth was predominantly driven by the doubling of the revenues from our cannabis vaping products in the United States and a rise in sales of tobacco vaping products in Europe.

    “Central to this success is our multi-pronged strategy: expanding our e-cigarette vaporizer technology sales and innovating our cannabis vaporizer offerings for both medical and recreational sectors. Our commitment to delivering industry-leading products has positioned Ispire at the forefront, cultivating a reputation for innovation and reliability,” said Michael Wang, the Co-Chief Executive Officer of Ispire. “The recent introduction of the Ispire ONETM technology in July 2023 further exemplifies our commitment to innovation and sets industry standards, particularly around consumer safety and operational efficiency. As part of our ongoing improvements, our California operations are set to launch our first fully automated assembly system by the end of December 2023.”

    The company also announced it is actively exploring Southeast Asia as a potential hub for future manufacturing operations, “aiming to further optimize” its production capabilities.

  • Kaival Brands Earns Initial Royalties From Philip Morris

    Kaival Brands Earns Initial Royalties From Philip Morris

    Kaival Brands Innovations Group, Inc, parent to Bidi Vapor, LLC (“Bidi Vapor”), received its first royalty payments from Philip Morris International, Inc. (PMI) for marketing Bidi Vapor products in multiple countries.

    In a press release, Kaival Brands announced that PMI achieved a record level of monthly sales in July for of its Bidi products that are marketed by PMI under the names VEEBA and VEEV NOW.

    Eric Mosser, Chief Executive Officer and President of Kaival Brands, said he was pleased to see the positive trajectory of sales and royalties to the company.

    “We are proud to work with Philip Morris and remain steadfast in our commitment to the responsible commercialization of better alternatives to cigarettes for adults who would otherwise continue smoking,” he said.

  • Dinner Lady Vape Suffers Massive Fire in UK Factory

    Dinner Lady Vape Suffers Massive Fire in UK Factory

    dinnerladyThe U.K. e-liquid and hardware brand Dinner Lady is attempting to leverage a network of overseas manufacturing facilities to maintain its product supply after a massive fire ripped through its factory last week .

    A company representative told The Grocer that “the majority of customers will not experience any change to their scheduled orders”.

    However, it also warned that some customers “may experience interruption.” The company will continue to take on new orders, a spokeswoman for Dinner Lady said.

    “Most importantly, we can report that no one was hurt in the fire and all our members are safe and well, thanks to the actions of our headquarters team and the local fire and emergency rescue teams,” the Dinner Lady spokeswoman added.

    The company said it wanted to “reassure our customers that our business operation is open and continuing as usual.”

    The factory was completely destroyed.

  • GTNF 2023: BAT Outlines 5-Step Vapor Rules Plan

    GTNF 2023: BAT Outlines 5-Step Vapor Rules Plan

    BAT has released a blueprint for how regulators and governments could better regulate vapor products and help smokers switch to less risky products.

    During DTNF 2023, held from Sept 18-20 in Seoul, BAT’s Global Head of Business Communications, Jonathan Atwood, told attendees how BAT’s five-step plan for regulation could support achieving the right balance between harm reduction and the unintended consequences of access, including underage use.

    Speaking on behalf of Kingsley Wheaton, BAT’s Chief Strategy & Growth Officer, Atwood said that reckless players in the market need to be penalized when they do not abide by the rules. He said the five suggestions are the areas that regulators should explore and establish “smart regulation” that is right for their market.

    “First, on-device technology and functionality: vapor products should be accessible only to adults. Both underage prevention and restriction is crucial. On-device technology, when applied and enforced across entire markets, could help in this regard.

    “Second, more recognition is needed that flavors are an important driver of adoption for smokers seeking alternatives. However, flavors in vapor products should not particularly appeal to anyone underage.

    “Third is at the manufacturing and import level: ensuring that non-compliant products cannot reach the market in the first place.

    “Fourth, where no restrictions exist already, regulators may want to look at who should be able to sell vapor products and where. Reasonable safeguards at the point-of-sale would help ensure these products are sold only to adult consumers. Solutions such as retail licensing and facial recognition technologies should be seriously considered.

    “Lastly, enforcement and penalties: governments must wield their power and ensure consumers are purchasing legitimate products. Such measures should be rigorously enforced and those who fail to comply should face meaningful sanctions.”

    Atwood said BAT was calling upon governments, regulators, and industry peers to rally towards a sustainable and progressive environment in which vaping products are sold and marketed responsibly.

  • Legal Insight

    Legal Insight

    Credit: Federico Magonio

    By Jean Gonnell, Christina Sava and Nicholas Ramos (Troutman Pepper Hamilton Sanders Tobacco and Cannabis Team)

    Across the United States hemp products seem to be everywhere. From corner stores to spas, one can find a hemp- or CBD-infused version of almost anything. Hemp and its derivatives are found in foods, cosmetics, hand-rolled cigarettes and vape pens. A new category of “intoxicating hemp products,” such as delta-8 THC products, have taken the hemp industry by storm. Although the market is vast, the regulatory landscape contains many pitfalls. Potential market entrants must carefully research the applicable laws, and take into account any federal-level risks, before deciding to invest in a hemp or hemp-derived products venture. This article reviews the legal status of hemp-derived products, including smokable hemp products, at the state and federal levels.

    Marijuana and Hemp

    Marijuana and hemp come from the same plant: Cannabis sativa L., or “cannabis” for short. Cannabis has a long history of industrial and medicinal uses, and only a short history of prohibition, which we now see unraveling. “Hemp” is the common term for cannabis with a concentration of delta-9 tetrahydrocannabinol (“THC”) of .3% and under, while “marijuana” is used to mean cannabis with a delta-9 THC concentration over .3%.  Marijuana remains a Schedule I substance under the Controlled Substances Act (“CSA”). Hemp production, on the other hand, was legalized by the Agricultural Improvement Act of 2018, or 2018 Farm Bill. At that time, Congress removed “hemp” and “tetrahydrocannabinols in hemp” from the CSA’s definition of “marijuana.” Specifically, the 2018 Farm Bill defined “hemp” as “the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis.” 7 U.S.C. § 1639o.

    So, although they are technically the same plant, hemp and marijuana fall under completely different regulatory regimes, with a single cannabinoid – delta-9 THC – determining whether a cannabis plant or product is hemp or marijuana.

    THC, CBD, and Other Cannabinoids

    There are over 100 cannabinoids found in cannabis. Perhaps the most well-known of these are cannabidiol, or CBD, and delta-9 THC. CBD is considered non-psychoactive and generally prized for its therapeutic potential. Delta-9 THC has long been recognized as the cannabinoid that causes users to feel “high.” Since the 2018 Farm Bill, however, other psychoactive THCs, such as delta-8 and delta-10 THC, have been identified in cannabis. The “high” produced by delta-8 THC has been described as partway between THC and CBD, with relaxing body effects and a less-potent “head-high,” while delta-10 has been described as producing a more cerebral high akin to sativa strains of marijuana.

    So why the boom in delta-8 and delta-10 THC products now? They can be derived from hemp. Although found in much lower quantities in hemp than other cannabinoids, manufacturers have found ways to chemically convert hemp-derived CBD into delta-8 and delta-10 THC. Even delta-9 THC is being converted from CBD, and manufacturers are adjusting product ratios to remain within the .3% limit. The Cannabis Regulators Association has called this the “0.3% loophole” and stated: “While the threshold of 0.3% delta-9 THC (tetrahydrocannabinol) by weight is a small amount of THC in a hemp plant, when applied to hemp-derived products (e.g., chocolate bars, beverages, etc.) which can weigh significantly more, 0.3% by weight can amount to hundreds of milligrams of THC. For example, a 50-gram chocolate bar at 0.3% THC would have around 150 mg of THC (30 times the standard 5 mg THC dose established by the National Institute on Drug Abuse).”[1]

    The Drug Enforcement Administration (DEA) more or less gave the hemp-derived delta-8 industry a green light in a September 2021 letter to the Alabama Board of Pharmacy. The Board of Pharmacy inquired as to the control status of delta-8 THC under the CSA. DEA concluded that “cannabinoids extracted from the cannabis plant that have a [delta-9]-THC concentration of not more than 0.3 percent meet the definition of ‘hemp’ and thus are not controlled under the CSA.” Thus, so long as delta-8, delta-10, and other extracts are derived from a cannabis plant with less than 0.3% delta-9 THC, they constitute “hemp,” which is federally legal.

    Notably, “synthetic tetrahydrocannabinols” remain a schedule I substance under the CSA. Some argue that because delta-8 and delta-10 are produced through a form of synthesis, they are Schedule I “synthetic tetrahydrocannabinols.” Regardless of this argument’s merit, this is not the position DEA has taken thus far, and we do not see any indication that they will suddenly take this position in the near future.

    FDA Enforcement and the Future of CBD Regulation

    Nonetheless, hemp-derived CBD and THC products are still not legal to be sold as a drug, dietary supplement, or food, according to the Food and Drug Administration (FDA). To the extent a manufacturer markets its delta-8 (or CBD) products as intended to affect the structure or any function of a consumer’s body, FDA’s position is that the product is an unapproved drug. In addition, “food” (almost anything edible that is not an approved drug or lawful dietary supplement) may not contain unapproved additives. Any form of CBD and THC are not approved food additives.

    FDA has also concluded that THC and CBD products cannot be marketed as dietary supplements, because the definition of “dietary supplement” excludes active ingredients that have been approved as drugs or have been authorized for investigation as a new drug. THC and CBD are both active ingredients in at least one FDA-approved drug. Other parts of the hemp plant that do not contain THC or CBD might be available for use as dietary supplements, so long as manufacturers abide by related requirements, including notifying FDA.

    And, FDA is watching the marketplace closely and taking enforcement action where it sees fit. FDA has issued numerous warning letters to companies selling hemp-derived CBD and THC products with impermissible health or therapeutic claims; for misbranding, such as lacking adequate directions for use; and for using these cannabinoids as an unapproved additive in foods, such as gummies, chocolate, caramels, chewing gum, and peanut brittle. The agency has also published a general health warning for delta-8 products.

    Industry and regulators alike have been anticipating some kind of regulatory action by FDA, but it appears this is yet far off. In January of this year, FDA determined that it does not have the appropriate regulatory pathway to regulate CBD products and called on Congress to pass legislation creating a new pathway separate from the food, drug, or dietary supplement pathway. Despite this regulatory uncertainty, sales of CBD products in the U.S. continue and could reach as high as $20 billion by 2025.

    States and Hemp-Derived Products

    Given the lack of federal standards and delta-8 and delta-10 (and likely other THCs’) psychoactive effects, state lawmakers are taking action to regulate products containing these extracts. At least 22 states have restricted or banned the sale of delta-8 THC products, while others are in the process of reviewing the cannabinoid’s status. One common way states are doing this is by limiting the total concentration of THC a product can have, rather than mirroring federal law and limiting only delta-9 THC concentrations. In Colorado, lawmakers have passed SB23-271, which goes further and actually classifies nonintoxicating cannabinoids, potentially intoxicating cannabinoids, and intoxicating cannabinoids. Products will be regulated according to which category of cannabinoids they contain.

     In many states, a “ban” actually means that these products will only be available in licensed cannabis dispensaries where regulators can more easily track their production and sale, ensure that the products pass required contaminant testing, and prevent the products from being sold to minors. Retailers and manufacturers of hemp derived products, especially those wanting to sell nation-wide, must be diligent in tracking state by state restrictions on hemp-derived products.

    Smokable Hemp

    Smokable hemp, although it receives less attention than other forms of hemp products, is a major driver of hemp product sales. Smokable hemp is hemp flowers after they have been manicured and dried. Smokable hemp can be sold as “buds” or in pre-rolled hemp cigarettes. This hemp looks and smells a lot like traditional marijuana but is not psychoactive. While some users may feel a mild mellowing effect, most do not feel “high” after smoking hemp. This may be why smokable hemp is the only hemp product category that has experienced wholesale price increases over time.

    The legal status of smokable hemp, however, also varies from state to state. Smokable hemp is illegal for sale in a handful of states, including Idaho, Iowa, Kentucky and Massachusetts. Other states do not place any restriction on its sales.

    New York has banned hemp flower products that are “clearly labeled or advertised for the purpose of smoking or in the form of a cigarette, cigar or pre-roll.” California does not currently permit the sale of any “inhalable hemp” products, however labeled, having passed a law that prohibits the sale of such products until a tax on the products has been enacted. No such tax is yet in effect.

    ***

    Given the above, it is not safe to assume that your hemp product is legal for sale because hemp is federally legally. It is important for retailers and manufacturers to be aware of the laws that apply to the types of hemp products they are selling. Although the DEA has been hands-off since the passage of the 2018 Farm Bill, FDA oversees all foods, drugs, and dietary supplements in the U.S. and maintains that THC and CBD, even though hemp derived, may not be added to foods and dietary supplements, or marketed as drugs. FDA does not oversee inhalable substances generally, and thus has not released statements related to the legality of smokable hemp. Smokable hemp may be a good market entry point, especially for manufacturers and retailers already familiar with highly-regulated inhalable products.  

    Troutman Pepper’s Cannabis Practice provides advice on issues related to applicable state law. Cannabis remains an illegal controlled substance under federal law. Its attorneys are available to provide more information about these opportunities.


    [1] See https://www.cann-ra.org/news-events/sx2s63c2fudq9n0zmk4ekviku9747f.

  • Wales: Lawmakers Call for Ban on Single-Use Vapes

    Wales: Lawmakers Call for Ban on Single-Use Vapes

    wales
    Credit: Jeffery

    The Welsh government is calling for a ban on disposable single-use vapes, according to media reports. The move would be “part of a suite of measures to address youth vaping”, Welsh ministers said.

    The Welsh government does not have the power to prohibit the vapes, but is calling on the UK government to do so. The UK Vaping Industry Association said banning disposable vapes was “not the answer” and instead called for action against retailers who sold the products to under-18s.

    Calls for a ban have been supported by the wildlife charity RSPCA Cymru, which says discarded vapes contain materials and poisonous substances including plastic, lithium and nicotine, which are all hazardous to animals.

    Wales joins lawmakers in Scotland and England in calling for a ban on disposable vaping products.

    The UK Vaping Industry Association’s director general, John Dunne, said banning the products could lead to black markets and increased smoking rates, leaving more people at risk.

    “We’ve always acknowledged that the issues of youth vaping and environmental impact of vapes need to be tackled,” he said. “However, it is clear that significantly increased enforcement is required against retailers who sell to minors.”

  • FEELM Highlights OS Vape During Intertabac 2023

    FEELM Highlights OS Vape During Intertabac 2023

    The latest in vaping industry innovations made its debut during InterTabac 2023, held from September 14-16, as FEELM, a leading closed system solution provider, unveiled its OS Vape in a partnership with OS.

    It is the first time FEELM has co-exhibited with its local partner during the world’s largest nicotine and tobacco trade show held in Dortmund, Germany.

    OS, a major player in Germany’s shisha product market, recently ventured into the disposable vaping product market.

    A representative from the FEELM booth said that collaborating with clients for exhibitions is a new strategy aimed at bolstering the client’s brand presence in local markets.

    The FEELM spokesperson said the company intends to continue its co-exhibition format at major global exhibitions, joining forces with clients from various regions in a collective march towards a global presence.

    OS Vape introduced a disposable vaping solution that delivers an elevated puff count, cost-efficiency, and unmatched vapor consistency, promising German consumers a rich vaping experience reminiscent of their cherished beers.

    The OS Vape uses FEELM Max ceramic coil technology, disposable product the ability to provide 800+ puffs, a more than 30% enhancement in puff count compared to other common disposable products.

    This establishes a new standard under TPD compliance, according to the FEELM spokesperson.

    “Beyond puff count, OS Vape offers an exceptional vapor and taste consistency of over 95%. These groundbreaking advancements have undoubtedly propelled the vaping industry to new zeniths,” the spokesperson said. “Additionally, the signature transparent e-liquid tank not only alleviates e-liquid concerns but also adds a touch of aesthetic sophistication.”

  • New York Opens State Cannabis Licensing to Public

    New York Opens State Cannabis Licensing to Public

    The New York State Cannabis Control Board on Tuesday voted to open up the application process starting next month for businesses seeking to sell, grow, process and distribute marijuana for adult use.

    Companies with an existing presence in the state’s medical program include Curaleaf Holdings , RIV Capital Inc. , a unit of Scotts Miracle-Gro Co. (SMG) that owns Etain dispensaries; Acreage Holdings Inc. , Green Thumb Industries and PharmaCann, according to Morningstar.

    Although adult-use cannabis has been legal since 2021 in New York State, only social equity applicants have received licenses thus far.

    The state said that starting Oct. 4, applications will be available through the New York Business Express Platform.

    “Today marks a pivotal step toward expanding and sustaining the state’s medical program and creation of an economically viable and equitable adult-use cannabis industry in New York,” said the New York Medical Cannabis Industry Association.

  • Grocer’s Lobby Wants ‘Nuanced Debate’ on Vapes

    Grocer’s Lobby Wants ‘Nuanced Debate’ on Vapes

    The Scottish Grocers’ Federation (SGF) trade association has written to Scotland’s public health minister Jenni Minto MSP, following the Programme for Government announcement, which said restrictions on vaping in Scotland will be considered.

    The SGF outlined a number of measures which it believes can reduce vaping among children, while also ensuring adult smokers looking to quit have access to alternative forms of nicotine, according to media reports.

    It said packaging and naming of vape brands should be changed to make them less appealing to children, but said it opposes restrictions on flavor.

    The SGF said flavor is shown to be the key factor which helps people switch from smoking to vaping – an alternative it argues is less harmful.

  • Australia: Vapers to be Hit by More Strict Rules

    Australia: Vapers to be Hit by More Strict Rules

    The Australian government has launched secret talks on introducing a strict near-complete ban on vaping in the country but has hidden the new proposals from the public, according to media reports. The rules could force traveler’s to the country to have a doctor’s note for any vape brought to the country.

    The Therapeutic Goods Administration – which oversees the approval of prescription drugs and medicines for the government – has revealed the secret plans in an official consultation paper.

    It outlines four proposals including a widespread ban on all single-use vapes, fruit-flavored vapes, personal importation of vaping products and all vaping ads. Only therapeutic nicotine vapes on prescription, available through pharmacies, would be allowed under the reforms – and they will only be tobacco or mild mint-flavored.

    Prescription vape liquid will also be banned from using any ingredients outside a limited list of medically-approved chemicals under the proposed legislation.

    All travelers to Australia will need to bring a prescription for their vape or a letter from their doctor, and be limited in how much vape they can bring into the country.  A consultation paper and feedback form is also hidden from public view and is not included in TGA’s list of other past and present consultation papers on its website.